Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership with Leading UK Private Clinic
LEXINGTON, Mass., January 28, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced its first commercial partnership with HCA Healthcare UK (United Kingdom), making its Revita® treatment commercially available for the first time for patients with type 2 diabetes. HCA Healthcare UK is the largest provider of privately funded healthcare in the UK and is part of the US-based HCA Healthcare, the world’s largest private hospital group. Revita is a first-in-class intervention designed to target insulin resistance and metabolic disease progression by resetting key pathways in the gut that drive metabolic disease. This minimally-invasive, outpatient, endoscopic procedure is a non-drug and…
Allurion expands in Natick, raises $60M
Allurion, a Natick company making a gastric weight-loss balloon that doesn’t require an operation, doesn’t yet have regulatory approval to sell in the United States. But Allurion does sell the Elipse Balloon in Europe and the Middle East, and with 15,000 sold in its three years in those markets, Allurion has made a major expansion with high hopes. “It’ll allow us to touch the lives of millions, if not billions, of people around the world,” Shantanu Gaur, Allurion’s CEO and co-founder, said Friday, officially opening the company’s new 10,000-square-foot office and lab on Erie Drive in Natick. The new space…
Fractyl’s Revita DMR Same-Day Therapeutic Procedure Could End Daily Insulin Injections for Type 2 Diabetes Patients
Interim clinical data to be presented at ADA 2019 show that approximately 85 percent of patients are insulin-free at six months after Revita DMR outpatient therapy LEXINGTON, Mass., June 8, 2019 — Fractyl Laboratories Inc. (Fractyl), today announced the presentation of interim data from the investigator-initiated INSPIRE clinical trial in collaboration with Fractyl showing Revita™ DMR, a same-day therapeutic procedure, can help eliminate the need for daily insulin injections for type 2 diabetes (T2D) patients. This data will be presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco on Sunday, June 9 from 12 pm to 1 pm….
Allurion Expands Digital Offering For Patients and Providers in Response to COVID-19
NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, is supporting customers around the world during COVID-19 with an expanded digital offering. The company’s weight loss program includes the world’s first and only procedureless gastric balloon, an individualized nutritional program, and a Bluetooth® smart scale and smartphone app that facilitate remote tracking. In response to recent data that indicates that individuals with obesity are at higher risk of poorer outcomes from COVID-19 and that quarantine measures may lead to weight gain, the company has expanded access to telenutrition for both existing…